ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00000626
Recruitment Status : Completed
First Posted : August 31, 2001
Last Update Posted : May 23, 2012
Sponsor:
Collaborator:
Amgen
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Primary Completion Date : No date given
  Actual Study Completion Date : February 1999
Publications:
Levine AM, Li P, Cheung T, Tulpule A, Von Roenn J, Nathwani BN, Ratner L. Phase II Study of Figrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease (ACTG 149). J Acquir Immune Defic Syndr. 2000 Aug 15; 24(5): 444-50
Levine AM, et al. Prospective, multicenter phase II trial of ABVD chemotherapy with G-CSF in HIV-infected patients with Hodgkin's disease (HD): AIDS Clincial Trials Group (ACTG) Study 149. Proc Annu Meet Am Soc Clin Oncol. 1997;16:A194